- Markets
- Healthcare
- KABRADG
KABRADG
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Kabra Drugs Approves Raising Of Funds Via Issue Of Shares Worth Upto 422.6 Million Rupees
Dec 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS - APPROVES RAISING OF FUNDS VIA ISSUE OF SHARES WORTH UPTO 422.6 MILLION RUPEES
KABRA DRUGS - ISSUE OF SHARES ON PREFERENTIAL ALLOTMENT BASIS
Further company coverage: KABD.BO
(([email protected];))
Dec 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS - APPROVES RAISING OF FUNDS VIA ISSUE OF SHARES WORTH UPTO 422.6 MILLION RUPEES
KABRA DRUGS - ISSUE OF SHARES ON PREFERENTIAL ALLOTMENT BASIS
Further company coverage: KABD.BO
(([email protected];))
Kabra Drugs Approves Raising Of Funds For An Issue Up To 20 Mln Shares
Nov 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
APPROVES RAISING OF FUNDS FOR AN ISSUE UP TO 20 MILLION SHARES
Source text: ID:nBSE8jDGYm
Further company coverage: KABD.BO
(([email protected];;))
Nov 4 (Reuters) - Kabra Drugs Ltd KABD.BO:
APPROVES RAISING OF FUNDS FOR AN ISSUE UP TO 20 MILLION SHARES
Source text: ID:nBSE8jDGYm
Further company coverage: KABD.BO
(([email protected];;))
Kabra Drugs To Consider Raising Of Funds
Oct 21 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSE13Sh4t
Further company coverage: KABD.BO
(([email protected];))
Oct 21 (Reuters) - Kabra Drugs Ltd KABD.BO:
KABRA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSE13Sh4t
Further company coverage: KABD.BO
(([email protected];))
Kabra Drugs To Consider And Approve Proposal Of Fund Raising
Jan 18 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO CONSIDER AND APPROVE PROPOSAL OF FUND RAISING
Further company coverage: KABD.BO
(([email protected];))
Jan 18 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO CONSIDER AND APPROVE PROPOSAL OF FUND RAISING
Further company coverage: KABD.BO
(([email protected];))
Kabra Drugs To Discuss About Expansion And Brining In New Business
Dec 8 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO DISCUSS ABOUT EXPANSION AND BRINING IN NEW BUSINESS
Source text for Eikon: ID:nBSE7tFZ75
Further company coverage: KABD.BO
(([email protected];))
Dec 8 (Reuters) - Kabra Drugs Ltd KABD.BO:
TO DISCUSS ABOUT EXPANSION AND BRINING IN NEW BUSINESS
Source text for Eikon: ID:nBSE7tFZ75
Further company coverage: KABD.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Kabra Drugs do?
Founded in 1989, Kabra Drugs Ltd is a pharmaceutical company based in Indore, Madhya Pradesh. They specialize in manufacturing injectables, liquids, soft gel caps, solvents, and anaesthetics under Segment A.
Who are the competitors of Kabra Drugs?
Kabra Drugs major competitors are Zenith Health Care, Ishita Drugs & Inds., Adeshwar Meditex, Vineet Laboratories, Omkar Pharmachem, Veerhealth Care, Concord Drugs. Market Cap of Kabra Drugs is ₹26 Crs. While the median market cap of its peers are ₹30 Crs.
Is Kabra Drugs financially stable compared to its competitors?
Kabra Drugs seems to be less financially stable compared to its competitors. Altman Z score of Kabra Drugs is 0 and is ranked 8 out of its 8 competitors.
Does Kabra Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Kabra Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Kabra Drugs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances
How strong is Kabra Drugs balance sheet?
Kabra Drugs balance sheet is weak and might have solvency issues
Is the profitablity of Kabra Drugs improving?
No, profit is decreasing. The profit of Kabra Drugs is -₹0.74 Crs for Mar 2024, -₹0.34 Crs for Mar 2023 and -₹0.19 Crs for Mar 2022
Is the debt of Kabra Drugs increasing or decreasing?
Yes, The debt of Kabra Drugs is increasing. Latest debt of Kabra Drugs is -₹1.45 Crs as of Sep-24. This is greater than Mar-24 when it was -₹3.52 Crs.
Is Kabra Drugs stock expensive?
Kabra Drugs is not expensive. Latest PE of Kabra Drugs is 0.0, while 3 year average PE is 10.6. Also latest EV/EBITDA of Kabra Drugs is 0.0 while 3yr average is 25.7.
Has the share price of Kabra Drugs grown faster than its competition?
Kabra Drugs has given better returns compared to its competitors. Kabra Drugs has grown at ~46.28% over the last 3yrs while peers have grown at a median rate of 0.27%
Is the promoter bullish about Kabra Drugs?
There is Insufficient data to gauge this.
Are mutual funds buying/selling Kabra Drugs?
There is Insufficient data to gauge this.